干扰素γ-1b预防危重患者医院获得性肺炎:2期安慰剂对照随机临床试验
本研究为多中心、安慰剂对照、随机2期试验,纳入11家欧洲医院收治的机械通气合并一个以上急性器官衰竭的危重成人,随机接受干扰素γ-1b(100 µg每48小时,第1至9天)或安慰剂。主要终点为28天医院获得性肺炎或全因死亡的复合终点。109例随机患者中,干扰素γ组26/55(47.3%)与安慰剂组16/53(30.2%)发生主要终点事件(校正HR 1.76,95%CI 0.94-3.29;P=0.08),差异未达统计学显著。试验在第二次安全性分析后因干扰素γ-1b潜在伤害而提前终止,严重不良事件干扰素γ组24/55(43.6%)vs 安慰剂组17/54(31.5%)(P=0.19)。
要点
- 机械通气合并急性器官衰竭患者中,干扰素γ-1b 100 µg每48小时第1至9天组28天医院获得性肺炎或死亡26/55(47.3%),安慰剂组16/53(30.2%),校正HR 1.76(95%CI 0.94-3.29;P=0.08),未达统计学显著。
- 试验在第二次安全性分析后因干扰素γ-1b潜在伤害而提前终止,计划样本量200例,实际随机109例(中位年龄57(41-66)岁;女性37例(33.9%);均在法国纳入),108例(99%)完成试验。
- 严重不良事件干扰素γ组24/55(43.6%)vs 安慰剂组17/54(31.5%)(P=0.19)。
- 探索性分析发现,医院获得性肺炎发生于对干扰素γ治疗CCL17反应降低的患者亚组中。
适用人群与场景
- 11家欧洲医院收治的危重成人,合并一个以上急性器官衰竭并接受机械通气,均在法国纳入。
处置流程与药物剂量
- 干扰素γ-1b 100 µg每48小时,从第1天至第9天,与安慰剂组方案相同。
研究设计与关键结果
- 多中心、安慰剂对照、随机2期试验,计划样本量200例,于入组50例和100例后进行中期安全性分析;第二次安全性分析后因干扰素γ-1b潜在伤害而终止试验,随访于2022年6月完成。
- 共随机109例(中位年龄57(41-66)岁;女性37例(33.9%);均在法国纳入),108例(99%)完成试验。
- 28天主要复合终点(医院获得性肺炎或全因死亡):干扰素γ组26/55(47.3%)vs 安慰剂组16/53(30.2%),校正HR 1.76(95%CI 0.94-3.29;P=0.08)。
- 严重不良事件:干扰素γ组24/55(43.6%)vs 安慰剂组17/54(31.5%)(P=0.19)。
- 探索性分析:医院获得性肺炎发生于对干扰素γ治疗CCL17反应降低的患者亚组中。
证据类型、等级与局限
- 证据类型:多中心、安慰剂对照、随机2期临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在机械通气合并急性器官衰竭的危重患者中,与安慰剂相比,干扰素γ-1b未显著降低28天医院获得性肺炎或死亡发生率。
- 试验因对干扰素γ-1b治疗的安全性担忧而提前终止。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We aimed to determine whether interferon gamma-1b prevents hospital-acquired pneumonia in mechanically ventilated patients.
METHODS: In a multicenter, placebo-controlled, randomized trial conducted in 11 European hospitals, we randomly assigned critically ill adults, with one or more acute organ failures, under mechanical ventilation to receive interferon gamma-1b (100 µg every 48 h from day 1 to 9) or placebo (following the same regimen). The primary outcome was a composite of hospital-acquired pneumonia or all-cause mortality on day 28. The planned sample size was 200 with interim safety analyses after enrolling 50 and 100 patients.
RESULTS: The study was discontinued after the second safety analysis for potential harm with interferon gamma-1b, and the follow-up was completed in June 2022. Among 109 randomized patients (median age, 57 (41-66) years; 37 (33.9%) women; all included in France), 108 (99%) completed the trial. Twenty-eight days after inclusion, 26 of 55 participants (47.3%) in the interferon-gamma group and 16 of 53 (30.2%) in the placebo group had hospital-acquired pneumonia or died (adjusted hazard ratio (HR) 1.76, 95% confidence interval (CI) 0.94-3.29; P = 0.08). Serious adverse events were reported in 24 of 55 participants (43.6%) in the interferon-gamma group and 17 of 54 (31.5%) in the placebo group (P = 0.19). In an exploratory analysis, we found that hospital-acquired pneumonia developed in a subgroup of patients with decreased CCL17 response to interferon-gamma treatment.
CONCLUSIONS: Among mechanically ventilated patients with acute organ failure, treatment with interferon gamma-1b compared with placebo did not significantly reduce the incidence of hospital-acquired pneumonia or death on day 28. Furthermore, the trial was discontinued early due to safety concerns about interferon gamma-1b treatment.
参考来源
- Roquilly A, Francois B, Huet O, et al. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Med. 2023. PMID: 37072597. doi:10.1007/s00134-023-07065-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。